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Introduction
Adequate functioning of the coagulation cascade, which involves a series of sequential proteolytic reactions that activate coagulation factors and eventually result in the formation of a fibrin clot, is needed for effective hemostasis. Factor VIII (FVIII) is a 2332 amino acid glycoprotein with a discrete domain structure (A1-a1-A2-a2-B-a3-A3-C1-C2) [1] [2] [3] that functions as a cofactor for activated FIX (FIXa) in the pathway of the coagulation cascade. On secretion, FVIII is predominantly processed into a heterodimer containing a heavy chain (A1-a1-A2-a2-B) and a light chain (a3-A3-C1-C2) that are non-covalently bound via a metal ion through the A1 domain and the A3 domain [1] [2] [3] [4] [5] . This heterodimer circulates in a complex with von Willebrand factor (VWF) [1] . Activation of FVIII through proteolytic cleavage by thrombin generates an activated FVIII (FVIIIa) heterotrimer (A1a1/A2a2/A3-C1-C2) [6] , which is released from VWF. FVIIIa binds to the phospholipid bilayer of activated platelets, and forms the tenase complex with FIXa in the presence of calcium ions to activate FX [1, 7] .
Hemophilia A is a congenital disorder in which different types of defect in the FVIII gene (F8) lead to a qualitative or quantitative deficiency of FVIII protein and subsequent activity, resulting in prolonged bleeding after trauma and recurrent spontaneous bleeding episodes. The mainstay of treatment for hemophilia A is replacement therapy with plasma-derived FVIII (pdFVIII) or recombinant FVIII (rFVIII) concentrates, which include fulllength rFVIII proteins and modified rFVIII proteins with deletion or truncation of the B domain. New further modified rFVIII proteins, including a B-domain-truncated single-chain construct composed of covalently bonded heavy and light chains, and two-chain rFVIII proteins incorporating the fragment crystallizable (Fc) region of immunoglobulin (Fc fusion) or covalent attachment of poly(ethylene glycol) (PEG) molecules, have been developed.
In this review, we discuss the history and current situation relating to the use of the one-stage clotting assay (OSA) and the chromogenic substrate assay (CSA) for both manufacturers' potency assignment and the diagnosis and clinical monitoring of FVIII:C measurements in patients with hemophilia A.
FVIII activity assays

OSA
The one-stage activated partial thromboplastin time (APTT) clotting assay measures activity of the intrinsic and common pathways of the coagulation cascade. The first diagnostic test for hemophilia A was proposed in 1953, in which evidence of hemophilia A was provided if the patient's plasma sample (test sample) showed a normal prothrombin time and a prolonged partial thromboplastin time as compared with 'normal' plasma (reference sample) [8] . FVIII activity was quantified by measuring the ability of 'normal' plasma to shorten/correct the partial thromboplastin time when added to hemophilic plasma. The fundamental methodology of the OSA has not changed over time. Serial dilutions of the test plasma sample are mixed with equal volumes of FVIII-deficient plasma plus phospholipids and surface activator reagents; calcium ions are then added to start the coagulation reaction, and the APTT is recorded (Fig. 1A ) [9] . The OSA is used with naturally or artificially depleted FVIII-deficient plasma. Technical developments include the introduction of combined phospholipid/activator reagents to aid automation [10] .
CSA
The CSA is based on the same principle as the two-stage clotting assay [11] . The common first stage involves incubation of the plasma sample with FIXa, FX in excess, thrombin (optional), calcium ions and phospholipids to generate activated FX (FXa). The FVIII is activated, and the resulting FVIIIa acts as a cofactor for FIXa to convert FX to FXa. This is followed by a second stage to determine the amount of FXa produced. The CSA was developed after the synthesis of FXa-selective chromogenic substrates [12, 13] . In the second step, FXa hydrolyzes the chromogenic substrate, and the color intensity of the resulting product (generally, p-nitroaniline released enzymatically) is directly proportional to the amount of FXa, which in turn is directly proportional to the amount of FVIII in the sample (Fig. 1B) ; therefore, the composition of assay components ensures quantitative assessment of FVIII activity [14] .
Comparison of OSA and CSA Both assays must fulfill three main requirements: they must provide a robust measure of FVIII activity, be sensitive to changes in pharmacokinetics, and be representative of the in vivo situation. In common with the OSA, the CSA is an indirect method of measuring FVIII activity, with the FVIII level being determined by comparison with a reference curve. Key features, advantages, and limitations of the OSA and the CSA are shown in Table 1 .
Historically, the CSA has been technically more complex to perform and more difficult to automate than the OSA, although protocols are available for the CSA on most modern automated equipment and are easy to perform. The CSA is also perceived as the slightly more expensive option, although this may depend on how the assay is implemented [15, 16] . A further difference is that clotting factors other than FVIII are present at physiologic concentrations, whereas, in the CSA, the initial FXa generation step is performed with concentrations of exogenous FX and FIXa as optimized by the kit manufacturer, and a low concentration of bovine thrombin may be present in order to accomplish activation of FVIII. Preactivation of FVIII increases activity in the OSA but not in the CSA (provided that FXa production is measured after a sufficiently long activation period), and the OSA is more likely to be affected by impurities such as lipids or heparin [17] . In both the OSA and the CSA performed on samples collected from patients receiving direct-acting oral anticoagulants, artefacts may appear, with the observed FVIII concentration being reduced [18] . Discussion continues over which assay is best and provides a better indication of 'true' FVIII activity [19] [20] [21] . Whichever assay is used, coagulant activity may be expressed in IU dL À1 , in IU mL À1 , or as a percentage. The FVIII reference range is 50-150 IU dL À1 , 0.5-1.5 IU mL
À1
, or 50-150%; however, there is now a preference for avoiding the reporting of activity as a percentage. It is worth noting that both the OSA and the CSA can be used in inhibitor assays, and it appears that the CSA produces fewer false-positive results; however such conclusions must be drawn cautiously [22] .
Use of the CSA and OSA: potency assignment of FVIII Potency assignments of both pdFVIII and rFVIII concentrates are required before release of an FVIII product by regulatory authorities. FVIII potency measurement must be accurate, as the two main purposes of potency labeling of products are to define the quantity of active substance in a vial and to guide dosing for treatment [23] . For example, potency assignments are determined relative to the current World Health Organization (WHO) International Standards (ISs) for FVIII [23] and are reported in international units. These potency assignments must be accurate to enable comparison between different products (pdFVIII and rFVIII) and to ensure that products labeled in international units contain the correct amount of FVIII in the vial versus the labeled potency, and are therefore not overpriced or underpriced. Furthermore, accurate potency determination is vital to ensure optimal safety and efficacy for patients, and to uphold the integrity of the international unit. The dose based on the labeled potency of a product and the expected FVIII recovery in the patient should be established with data from clinical pharmacokinetic studies [23] . A dosing guideline may then be derived from which clinicians should be able to determine the optimal efficacious and safe dose for a specific patient. If manufacturers accurately and precisely determine the amount of FVIII in a drug product, a clinician can be confident in the international unit assignment and the appropriate dose based on standard clinical practice parameters, established pharmacokinetic data from clinical trials, and product labeling guidance.
Currently, the OSA and the CSA are used to assign potency. The European Medicines Agency (EMA) requires the CSA to be used. However, although the EMA stipulates that the CSA should be used, approval of the OSA for potency labeling by regulators is possible, albeit infrequently sought, provided that equivalence of results obtained with both methods is shown [24] . The US Food and Drug Administration (FDA) has no such guidance; currently all but two FVIII products are labeled by use of the OSA. Because the majority of laboratories in the USA use the OSA to monitor, the FDA's preference has been to label by use of the OSA, but decisions on potency labeling should not be driven by a desire to adapt to standard clinical laboratory practice; rather, it should be supported by thorough characterization of the in vitro properties of the new product and data on in vivo efficacy. The Subcommittee of the Scientific and Standardization Committee of the ISTH (SSC ISTH) has published recommendations for potency labeling as a guidance to manufacturers; these state that harmonization of the approach for assigning potency is vital, particularly for the new modified rFVIII products [23] . The method of choice for labeling is irrelevant when both the OSA and CSA agree, but it is crucial when there are significant discrepancies. An example of potency labeling issues occurred with ReFacto (Pfizer, Sandwich, UK). The results from a different study revealed that the CSA-assigned potency for the product-specific ReFacto laboratory standard (RLS) was~20% too high [25] .
Subsequently, the RLS was recalibrated, and this resulted in a 20% increase in the ReFacto protein level in each vial for the same labeled potency. Consequently, the therapeutic potential of ReFacto may have been overestimated by the previous potency label [26] , and this may explain early reports of poorer efficacy of B-domain deletion (BDD) products than would be expected on the basis of the labeled potency [27] [28] [29] . Owing to the differences in potencies assigned by the OSA and the CSA, the successor products have different labeled potencies in the USA and the European Union (EU), with 1 IU of Xyntha (Wyeth Pharmaceuticals, Collegeville, PA, USA) (USA; OSA) being equivalent to 1.38 IU of ReFacto AF (Pfizer, Sandwich, UK) (EU; CSA) [30] .
Use of the CSA and the OSA: clinical monitoring
The diagnosis of hemophilia A, monitoring of FVIII target levels during treatment, determination of the pharmacokinetics of FVIII replacement therapies, and the successful perioperative management of FVIII levels in patients with hemophilia A require estimates of FVIII:C with acceptable levels of accuracy and precision. In practice, variability of approximately 10-20% is tolerated for clinical monitoring, owing to the inherent differences in pharmacokinetic and clinical efficacy responses of individual patients to FVIII replacement products. The impact of discrepancies between the OSA and the CSA in clinical practice has recently been reviewed, with an emphasis on diagnosis and the management of inhibitors [11] . Overall, the OSA remains widely used for the diagnosis of hemophilia A and clinical monitoring of FVIII replacement therapy, because it is simple, rapid, inexpensive, and easy to automate.
Although the OSA is widely used, there are numerous assay kits, reagents, assay conditions, analyzers, and combinations thereof available for the OSA, leaving the method riddled with variation. The interlaboratory variability of the OSA increases if the recommended technical standardization procedures are not followed [17] ; these include the use of FVIII-deficient plasma containing a normal level of VWF, inclusion of albumin (1% w/v) in all assay buffers, and predilution with hemophilic plasma (or its equivalent) for the assay of all rFVIII or high-purity pdFVIII concentrates [17, 31] . Standardization of assay procedures has reduced the variations observed for the OSA in collaborative studies to some extent [32] [33] [34] . Although the OSA accurately assesses FVIII activity for pdFVIII, it has a tendency to underestimate FVIII activity for some rFVIII products, particularly BDD rFVIII proteins, with OSA-based estimates often being 20-50% below chromogenically determined values [34] [35] [36] [37] [38] . Manufacturers will need to provide guidance to clinicians whose laboratories are using the OSA to measure FVIII:C of products that have been clinically validated and then labeled by use of the CSA, in order to allow appropriate interpretation of OSA data.
The CSA is currently in use in many specialty clinical laboratories [39] , and validation of the CSA for routine clinical laboratory environments is currently under investigation [40] . In Europe, it is accepted that the CSA shows lower variation than the OSA [33, 34] . At low FVIII:C levels (3-5%), the CSA is considered to be more sensitive than the OSA [24] , and may show greater precision [41] , but the latter has not been consistently demonstrated [42, 43] . The CSA is generally more reproducible across laboratories ( Table 2 ). The improvements in sensitivity and precision obtained with the CSA over the OSA are clear advantages, but its complexity adds to the operator burden, and the additional step and reagents introduce a hypothetical risk of increased errors. The lower number of commercially available CSA kits than OSA kits may limit interlaboratory variation, but, conversely, reduced competition between manufacturers may sustain elevated prices. It is also possible that the effective cost of the CSA is increased by the limited use of the kit, as it is only suitable for assaying FVIII, unlike the OSA, which is a modification of the APTT assay used for routine coagulation monitoring, and by the lack of kits designed for assaying a small number of samples. The majority of CSA kits are formulated such that the whole CSA kit must be used for assaying, which may result in wastage in centers with few patients with hemophilia A. This limitation may be circumvented by aliquoting and freezing reagents, but utilization of stored frozen aliquots should be validated by any laboratory embarking on such a protocol.
Discrepancies between the OSA and the CSA Measurement of FVIII activity with the OSA and the CSA can provide comparable results, but discrepancies between the two types of assay occur in a number of circumstances. These include measurements of FVIII activity in patients with specific hemophilia A phenotypes or genetic mutations [21, 44] , and when high-purity pdFVIII concentrates and rFVIII products are assayed [34] [35] [36] [37] [38] . The discrepancies may be exacerbated by modifications to rFVIII, such as BDD [36] , the length of the B-domain linker [45] , and technologies designed to improve the pharmacokinetics of rFVIII, including PEGylation [41, 42, 46, 47] . The factors known to result in assay discrepancies are detailed in Table 2 .
Patients with non-severe hemophilia A Assay discrepancies have been observed in approximately one-third of patients with non-severe hemophilia A [21, 44] . The FVIII activity level may be higher when determined with the OSA than when determined with the chromogenic/two-stage assay [21, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] or vice versa [21, 55, 58, 59] .
Lower FVIII activity (≥ 2-fold difference) when measured with the CSA compared with the OSA is associated with the presence of missense mutations localized in the A1-A2-A3 domain interfaces, e.g. p.Arg546Trp, p.Arg550Gly and p.Arg550His [21, 54, 55, 60] , p.Asn713Ile [52] , and p.His1973Leu [56] . These mutations are associated with reductions in the stability of the FVIII heterodimer and A2 domain in the activated heterotrimer (FVIIIa), and disruption of interdomain protein-protein interactions [21, 54] . As FVIIIa is only generated once calcium ions have been added during the final rapid clotting stage of the OSA, the effect of instability of the FVIIIa heterotrimer is minimized. In contrast, during the incubation of the CSA first step, in which FVIII is proteolytically activated to form FVIIIa, a higher rate of A2 dissociation is favored, and would thus tend to reduce the observed FVIII activity [21, 54] .
Patients with mutations such as p.Tyr365Cys and p.Glu739Lys show higher levels of FVIII activity with the CSA than with the OSA [21, 44, 58, 59] . The majority of mutations associated with this type of discrepancy are located close to or within thrombin cleavage sites, or FIX-binding or VWF-binding sites, and thus affect thrombin activation or FVIII binding to FIXa or VWF [21] . In the OSA, the physiologic thrombin concentrations initially formed activate FVIII in a short period of time, making the assay sensitive to any alterations to thrombin binding or cleavage of FVIII. In contrast, the requirement for incubation in the CSA means that changes in the affinity of thrombin for FVIII and/or changes in the FVIII activation kinetics will be overcome by the excess thrombin activating diluted FVIII [21] .
In the majority of cases of hemophilia A, FVIII activity measured with either assay is low enough that the correct diagnosis will be made. However, approximately 5-10% of patients with mild hemophilia A show FVIII activity within the normal range when it is measured with one type of assay, but lower FVIII activity when it is measured with the other [21, 61] . In these patients, diagnosis may be missed if only one assay is used. In most cases, the clinical phenotype correlates more closely with the lower FVIII activity obtained from either of these assays [21, 61, 62] , but exceptions have been documented [63] . Thus, combined use of the OSA and the CSA is recommended for the diagnosis of mild hemophilia A [21, 44, 61, 62, 64, 65] .
Existing rFVIII products
Assay discrepancies have been noted for full-length rFVIII products, with higher FVIII activity levels being measured with the CSA than with the OSA [33] [34] [35] [36] [37] [38] . Generally, the discrepancies are 8-20% [33, 34, 36] , and thus not clinically significant (i.e. within the accepted variation of ≤ 20%), although reports of differences of approximately 40% exist [37] . However, the assay discrepancy for BDD rFVIII can be much larger, with the OSA giving values 20-50% lower than the CSA [34] [35] [36] [37] [38] . Plasma levels of the BDD rFVIII product ReFacto were up to approximately 50% lower when measured with the OSA than when measured with the CSA [36] . Laboratories using the OSA assay to measure ReFacto postinfusion plasma samples were provided with a product-specific reference standard to correct the underestimation.
Assay discrepancies have been observed for postinfusion samples of FVIII concentrates, with evidence that the difference is greater for rFVIII than for pdFVIII products. In the collaborative studies to calibrate the 5th and 6th WHO IS FVIII concentrates, the chromogenic/ one-stage potencies of a rFVIII concentrate versus the WHO plasma standard were 1.48 and 1.26, respectively [30] . In a UK survey of postinfusion samples, the CSA gave significantly higher results than the OSA for Kogenate FS (Bayer Pharma AG, Berlin, Germany) (32% difference; P < 0.0001) but not for Advate (Baxter AG, Vienna, Austria) or ReFacto AF, when calibrated with a plasma standard [66] . The APTT reagent type markedly affected one-stage FVIII activities for ReFacto AF and Advate, but not for Kogenate FS [66] . For plasma-derived products, the situation depends on the test systems and product type. A mAb-purified [68] . Postinfusion samples of recombinant and high-purity plasma-derived products are therefore regarded as concentrates diluted in a patient's plasma. To provide a 'like versus like' comparison, a concentrate standard (similar to the administered product) is proposed to be diluted in hemophilic plasma and used as the reference instead of a plasma standard [30] .
New modified rFVIII products
The advent of rFVIII products with additional modifications designed to improve the pharmacokinetic properties of FVIII presents further challenges for the determination of FVIII activity [66] . Potential assay discrepancies are under investigation for these new products, and the currently reported data are shown in Table 3 . It appears that BDD/truncation on its own does not necessarily lead to significant assay discrepancies. This is supported by the similar results for both Advate (full-length rFVIII) and NovoEight (Novo Nordisk A/S, Bagsvaerd, Denmark) (B-domain-truncated rFVIII) in a comparative field study [41] , in which, despite discrepancies between the OSA and CSA, their magnitude was similar. In addition, the comparative field study for Eloctate (Biogen, Cambridge, MA, USA) (rVIII-Fc fusion protein) concluded that clinically insignificant assay discrepancies occurred as compared with a full-length FVIII product [42] . In common with the NovoEight comparative field study, the OSA overestimated FVIII activity at low concentrations, and better dose linearity was observed for the CSA [41, 42] . Assay discrepancies have been noted for FVIII activity levels for the B-domain-truncated singlechain construct rVIII-SingleChain [69] , but data are not yet available on the extent of the discrepancies. The underlying reason why some B-domain modifications result in assay discrepancies remains to be elucidated, although it may be that the length of the B-domain linker is important [45] . Assay discrepancies that are likely to be clinically relevant are apparent for the N8-GP (Novo Nordisk A/S) and BAY 94-9027 (Bayer Pharma AG) PEGylated rFVIII products. Although the PEG moiety does not appear to affect the CSA, it does seem to interact with silica-based APTT reagents, resulting in prolonged APTT and underestimation of FVIII activity in the OSA [46, 47, 70] . Ellagic acid and polyphenol APTT reagents do not appear to cause these issues, and it may therefore still be possible to monitor PEGylated rFVIII products with the OSA [46, 47, 70] . For BAX 855 (Baxter Healthcare Corporation), a PEGylated full-length rFVIII, data have not been reported on assay discrepancies. However, a modified assay specific for PEGylated rFVIII that combines the use of an anti-PEG antibody with a CSA has recently been developed and validated for the measurement of BAX 855 [71] . Although the mechanism for interference of the PEG moiety with particular APTT reagents has not been elucidated, the size and position of the PEG molecule on the rFVIII protein may play a role [70, 72] .
Options for resolving FVIII assay discrepancies
When the product manufacturers' preferred method of clinical monitoring, such as the CSA, is not available there are several options for resolving FVIII activity assay discrepancies with the available clinical laboratory methods.
Product-specific reference standard
This method was used with ReFacto and its successor ReFacto AF, when the CSA was not available. Accurate FVIII activities could be determined for ReFacto and ReFacto AF with the OSA, as long as the RLS or RLS-AF standard was used, respectively, instead of a plasma standard [35, 73, 74] . There are several advantages to this approach: it facilitates the standardization of results between assays; it is consistent with the 'like versus like' principle recommended by the SSC ISTH; and it provides greater reliability for critical determination of FVIII activity (e.g. in clinical monitoring). However, disadvantages must also be considered. Using a productspecific standard can be difficult to implement in routine laboratory procedures. Each assay and product standard may need to be validated on specific analyzers, so switching between standards would be time-consuming. Additionally, as the number of rFVIII products increases, the number of accompanying reference standards will probably also increase. Integrating further multiple reference standards into standard laboratory practice may prove challenging, requiring good communication between the hemophilia treatment center and the laboratory. Not only would clinical laboratories that support patient monitoring need to be informed of the specific rFVIII product that the patient is receiving, but they would also have to indicate which product-specific standard was used to obtain the reported result. In summary, although a product-specific standard provides a method for accurately determining FVIII activity with the OSA, in reality it is unlikely that most clinical laboratories would embrace this change; rather, they would continue to use their own internal procedures. For PEGylated rFVIII products, product-specific standards may also be necessary for potency measurements; a product-specific standard for N8-GP is currently under evaluation [46, 47] . [46, 47] . The situation concerning other rFVIII modifications -BDD, B-domain truncation, and Fc fusion -is less clear. For these products, FVIII activity determination with the OSA without specifically recommended reagents may be feasible, but is likely to be productdependent.
Manufacturer-guided clinical interpretation
Acceptable clinical interpretation of the FVIII activity of products that produce systematic discrepancies across reagents may be possible if well characterized, and if a correction factor is applied according to the manufacturer's guidelines. However, the feasibility of this approach would need to be demonstrated for individual products, and would be dependent on the OSA underestimation being predictable across the entire range of FVIII:C values observed in clinical practice (the relationship may be non-linear) and the variability being consistent with other rFVIII full-length products.
Conclusions
New modified rFVIII products pose challenges for FVIII potency and activity measurement, and their behavior in both the OSA and the CSA must be fully characterized [23] . Despite being commonly used worldwide, because of its simplicity and widespread dissemination, the OSA has several limitations with respect to determination of FVIII activity levels for some BDD and other modified rFVIII products, particularly those that contain a PEG moiety. However, as it remains the method of choice in a number of countries, including the USA, options to convert inaccurate OSA results should be implemented and guided by the manufacturers, e.g. product-specific standards, avoidance of certain APTT reagents, or generalized guidance if there is systematic underestimation or overestimation of activity. Clinical interpretation of all patient laboratory data is necessary for appropriate clinical decision-making. As the laboratory practice adjusts to fully support clinical moni- toring of rFVIII activity in patients, the onus will be on clinicians. As manufacturers fully characterize the rFVIII products coming to market, appropriate guidance should be given regarding recommended laboratory methods and variance noted across methods used in current clinical practice. This will allow emergent interpretation of clinical results and permit clinicians to use alternative reference laboratories if needed in non-emergent settings. When reporting FVIII activity, laboratories will need to note, at a minimum, the current methods used in the laboratory, i.e. OSA or CSA, in addition to the activators used. Acceptable clinical interpretation of FVIII activity of products that produce systematic discrepancies across reagents may be possible if well characterized. This will be especially useful for ease of local laboratory evaluations when the local laboratory is unable to integrate multiple methods into practice. Currently, the CSA is used less frequently than the OSA for clinical monitoring. However, its precision and suitability across all FVIII concentrations make it an attractive option. The evolution of CSA use may be accelerated if it is used to perform potency measurements and clinical monitoring during phase III studies of new modified rFVIII products, but considerable barriers remain. Less expensive CSA kits and reagents, and kits designed for lower sample throughput, will be needed if clinical laboratories are to consider their routine use. Overall, the ability of the CSA to accurately measure the FVIII activity levels of new modified rFVIII products will increase its role in potency assignment and probably also in clinical monitoring in the future. Addendum F. Peyvandi, J. Oldenburg, and K. Friedman contributed to the design of this review, and identified the priorities and needs of the scientific community. F. Peyvandi coordinated the review. All authors critically reviewed the manuscript, providing substantial input, and gave final approval of the version to be published.
